Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Bradykinin b2 receptor antagonists
15 evidence topics · 9 sources
Icatibant: FDA-approved indication
Icatibant: dosing and maximum number of doses
Icatibant: self-administration
Icatibant: injection-site reactions
Icatibant: laryngeal attacks and interaction with ACE inhibitors
FAST-3: results as described in the FDA label
FAST-3: published primary and key secondary endpoints
“Cutaneous or abdominal attacks: icatibant significantly reduced median times (vs placebo) to 50% or more reduction in symptom severity (2.0 vs 19.8 hours; P < .001, primary endpoint), onset of primary symptom relief (1.5 vs 18.5 hours; P < .001, key secondary endpoint), or almost complete symptom relief (8.0 vs 36.0 hours; P = .012) and provided a shorter time to initial symptom relief (0.8 vs 3.5 hours; P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All icatibant-treated subjects experienced injection site reactions, but none reported clinically relevant changes in safety parameters or serious AEs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
FAST-1 and FAST-2: icatibant compared with placebo and with tranexamic acid
“In the For Angioedema Subcutaneous Treatment (FAST) 1 trial, patients received either icatibant or placebo; in FAST-2, patients received either icatibant or oral tranexamic acid, at a dose of 3 g daily for 2 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In FAST-1, the primary end point, the median time to clinically significant relief of the index symptom, was 2.5 hours in the icatibant group versus 4.6 hours in the placebo group (P = 0.14) (Table 2 and Fig. 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In FAST-2, the median time to clinically significant relief of the index symptom was 2.0 hours with icatibant versus 12.0 hours with tranexamic acid (P<0.001) (Table 2 and Fig. 1B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median time to almost complete relief of symptoms was 8.5 hours with icatibant versus 19.4 hours with placebo (P = 0.08) in FAST-1 (Table 2 and Fig. 2A) and 10.0 hours with icatibant versus 51.0 hours with tranexamic acid (P<0.001) in FAST-2 (Table 2 and Fig. 2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Icatibant: treatment of recurrent attacks in open-label extensions
Generic icatibant: SAJAZIR indication and dosing
Generic icatibant: number of approved generic products
Icatibant: timing of treatment and attack duration in the Icatibant Outcome Survey
“The Icatibant Outcome Survey is an international, prospective, observational study for patients treated with icatibant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Attack duration was significantly shorter in patients treated <1 hour of attack onset compared with those treated ≥1 hour (6.1 hours versus 16.8 hours [p<0.001]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Self-administrators were more likely to treat early and experience shorter attacks than those treated by a healthcare professional.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of attacks treated within 1 hour after attack onset was twice as high for self-administrators as for those who received HCP-administered icatibant (44% attacks versus 22% attacks, respectively; p = 0.001) (Figure 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Icatibant: guideline recommendation and redosing compared with C1 esterase inhibitor
“Both icatibant and C1-INH effectively reduce attack duration, with icatibant offering faster and more convenient self-administration but more frequently requiring a second dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that first-line ODT for HAE attacks include either IV C1-INH, icatibant or sebetralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote